Liposomes as vaccine delivery systems: A review of the recent advances

Therapeutic Advances in Vaccines

Volumn 2, Issue 6, 2014, Pages 159-182

  Schwendener, Reto A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Adjuvants; Antigens; Archaeosomes; Liposomes; Therapeutic cancer vaccines; Vaccines; Veterinary vaccines; Virosomes

Indexed keywords

EID: 84926435038     PISSN: 20510136     EISSN: None     Source Type: Journal    
DOI: 10.1177/2051013614541440     Document Type: Review

References (181)

1. Acres, B. and Limacher, J. (2005) Muc1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 4: 493-502.
2. Adler-Moore, J., Munoz, M., Kim, H., Romero, J., Tumpey, T., Zeng, H. et al. (2011) Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 29: 4460-4468.
3. Allison, A. and Gregoriadis, G. (1974) Liposomes as immunological adjuvants. Nature 252: 252.
4. Allison, A. and Gregoriadis, G. (1976) Liposomes as immunological adjuvants. Recent Results Cancer Res: 58-64.
5. Almeida, J., Edwards, D., Brand, C. and Heath, T.D. (1975) Formation of virosomes from influenza subunits and liposomes. Lancet 2: 899-901.
6. Alving, C. (1991) Liposomes as carriers of antigens and adjuvants. J Immunol Methods 140: 1-13.
7. Alving, C., Peachman, K., Rao, M. and Reed, S. (2012) Adjuvants for human vaccines. Curr Opin Immunol 24: 310-315.
8. Alving, C., Rao, M., Steers, N., Matyas, G. and Mayorov, A. (2012) Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines 11: 733-744.
9. Ambrosch, F., Wiedermann, G., Jonas, S., Althaus, B., Finkel, B., Gluck, R. et al. (1997) Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15: 1209-1213.
10. Amidi, M., De Raad, M., Crommelin, D., Hennink, W. and Mastrobattista, E. (2011) Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine. Syst Synth Biol 5: 21-31.
11. Amidi, M., Van Helden, M., Tabataei, N., De Goede, A., Schouten, M., De Bot, V. et al. (2012) Induction of humoral and cellular immune responses by antigenexpressing immunostimulatory liposomes. J Control Release 164: 323-330.
12. Anderson, P., Meyers, P., Kleinerman, E., Venkatakrishnan, K., Hughes, D., Herzog, C. et al. (2014) Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer 61: 238-244.
13. Andrews, C., Huh, M., Patton, K., Higgins, D., Van Nest, G., Ott, G. et al. (2012) Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity. Mol Pharm 9: 1118-1125.
14. Ansari, M., Zubair, S., Tufail, S., Ahmad, E., Khan, M., Quadri, Z. et al. (2012) Ether lipid vesicle-based antigens impart protection against experimental listeriosis. Int J Nanomedicine 7: 2433-2447.
15. Badiee, A., Khamesipour, A., Samiei, A., Soroush, D., Shargh, V., Kheiri, M. et al. (2012) The role of liposome size on the type of immune response induced in BALB/C mice against leishmaniasis: rgp63 as a model antigen. Exp Parasitol 132: 403-409.
16. Bal, S., Hortensius, S., Ding, Z., Jiskoot, W. and Bouwstra, J. (2011) Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 29: 1045-1052.
17. Balcarova, J., Helenius, A. and Simons, K. (1981) Antibody response to spike protein vaccines prepared from Semliki Forest virus. J Gen Virol 53: 85-92.
18. Barnier Quer, C., Elsharkawy, A., Romeijn, S., Kros, A. and Jiskoot, W. (2012) Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone. Eur J Pharm Biopharm 81: 294-302.
19. Barnier-Quer, C., Elsharkawy, A., Romeijn, S., Kros, A. and Jiskoot, W. (2013) Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators. Pharmaceutics 5: 392-410.
20. Benvegnu, T., Lemiegre, L. and Cammas-Marion, S. (2009) New generation of liposomes called archaeosomes based on natural or synthetic archaeal lipids as innovative formulations for drug delivery. Recent Pat Drug Deliv Formul 3: 206-220.
21. Bernstein, D., Earwood, J., Bravo, F., Cohen, G., Eisenberg, R., Clark, J. et al. (2011) Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 29: 2071-2078.
22. Bernstein, D., Farley, N., Bravo, F., Earwood, J., McNeal, M., Fairman, J. et al. (2010) The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 28: 3748-3753.
23. Borrero, R., Garcia Mde, L., Canet, L., Zayas, C., Reyes, F., Prieto, J. et al. (2013) Evaluation of the humoral immune response and cross reactivity against mycobacterium tuberculosis of mice immunized with liposomes containing glycolipids of Mycobacterium smegmatis. BMC Immunol 14 Suppl. 1: S13.
24. Bovier, P., Bock, J., Ebengo, T., Frosner, G., Glaus, J., Herzog, C. et al. (2010) Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis a vaccine. J Med Virol 82: 1629-1634.
25. Brignole, C., Marimpietri, D., Di Paolo, D., Perri, P., Morandi, F., Pastorino, F. et al. (2010) Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res 70: 9816-9826.
26. Brito, L., Malyala, P. and O’Hagan, D. (2013) Vaccine adjuvant formulations: a pharmaceutical perspective. Semin Immunol 25: 130-145.
27. Butts, C., Maksymiuk, A., Goss, G., Soulieres, D., Marshall, E., Cormier, Y. et al. (2011) Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137: 1337-1342.
28. Butts, C., Murray, R., Smith, C., Ellis, P., Jasas, K., Maksymiuk, A. et al. (2010) A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 11: 391-395.
29. Carroll, T., Matzinger, S., Barry, P., McChesney, M., Fairman, J. and Miller, C. (2014) Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/ DNA adjuvant. J Infect Dis 209: 24-33.
30. Carstens, M., Camps, M., Henriksen-Lacey, M., Franken, K., Ottenhoff, T., Perrie, Y. et al. (2011) Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine 29: 4761-4770.
31. Chen, C., Lin, Y., Liu, Y., He, P., Lin, C., Chiu, Y. et al. (2012) Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch. Int J Nanomedicine 7: 607-621.
32. Chen, L. and Flies, D. (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13: 227-242.
33. Cheng, G., Zhao, X., Yan, W., Wang, W., Zuo, X., Huang, K. et al. (2007) Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response. Vaccine 25: 5199-5208.
34. Christensen, D., Henriksen-Lacey, M., Kamath, A., Lindenstrom, T., Korsholm, K., Christensen, J. et al. (2012) A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J Control Release 160: 468-476.
35. Christensen, D., Korsholm, K., Andersen, P. and Agger, E. (2011) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 10: 513-521.
36. Cote, P., Butler, S., George, A., Fairman, J., Gerin, J., Tennant, B. et al. (2009) Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant. J Med Virol 81: 1760-1772.
37. Cruz, L., Rueda, F., Simon, L., Cordobilla, B., Albericio, F. and Domingo, J. (2014) Liposomes containing NY-ESO-1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines. Nanomedicine (Lond) 9: 435-449
38. De Bernardis, F., Amacker, M., Arancia, S., Sandini, S., Gremion, C., Zurbriggen, R. et al. (2012) A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 30: 4490-4498.
39. Desel, C., Werninghaus, K., Ritter, M., Jozefowski, K., Wenzel, J., Russkamp, N. et al. (2013) The Mincle-activating adjuvant TDB induces MyD88dependent Th1 and Th17 responses through IL-1R signaling. PLoS One 8: e53531.
40. Dietrich, G., Hess, J., Gentschev, I., Knapp, B., Kaufmann, S. and Goebel, W. (2001) From evil to good: a cytolysin in vaccine development. Trends Microbiol 9: 23-28.
41. Ding, Q., Chen, J., Wei, X., Sun, W., Mai, J., Yang, Y. et al. (2013) Raftsomes containing epitopeMHC-II complexes mediated CD4+ T cell activation and antigen-specific immune responses. Pharm Res 30: 60-69.
42. Dissanayake, D., Wijewardana, T., Gunawardena, G. and Poxton, I. (2010) Potential use of a liposomeencapsulated mixture of lipopolysaccharide core types (R1, R2, R3 and R4) of Escherichia coli in controlling colisepticaemia in chickens. J Med Microbiol 59: 100-107.
43. Dong, L., Liu, F., Fairman, J., Hong, D., Lewis, D., Monath, T. et al. (2012) Cationic liposomeDNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a prepandemic influenza a H5N1 vaccine in mice. Vaccine 30: 254-264.
44. Engler, O., Schwendener, R., Dai, W., Wolk, B., Pichler, W., Moradpour, D. et al. (2004) A liposomal peptide vaccine inducing CD8+ T cells in HLAA2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine 23: 58-68.
45. Erikci, E., Gursel, M. and Gursel, I. (2011) Differential immune activation following encapsulation of immunostimulatory CPG oligodeoxynucleotide in nanoliposomes. Biomaterials 32: 1715-1723.
46. Even-Or, O., Joseph, A., Itskovitz-Cooper, N., Samira, S., Rochlin, E., Eliyahu, H. et al. (2011) A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine 29: 2474-2486.
47. Fairman, J., Moore, J., Lemieux, M., Van Rompay, K., Geng, Y., Warner, J. et al. (2009) Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin 5: 141-150.
48. Faisal, S., Chen, J., McDonough, S., Chang, C., Teng, C. and Chang, Y. (2011) Immunostimulatory and antigen delivery properties of liposomes made up of total polar lipids from non-pathogenic bacteria leads to efficient induction of both innate and adaptive immune responses. Vaccine 29: 2381-2391.
49. Faisal, S., Yan, W., McDonough, S., Chang, C., Pan, M. and Chang, Y. (2009) Leptosome-entrapped leptospiral antigens conferred significant higher levels of protection than those entrapped with PC-liposomes in a hamster model. Vaccine 27: 6537-6545.
50. Fan, Y., Wang, D., Hu, Y., Liu, J., Han, G., Zhao, X. et al. (2012) Liposome and epimedium polysaccharide-propolis flavone can synergistically enhance immune effect of vaccine. Int J Biol Macromol 50: 125-130.
51. Figueiredo, L., Cadete, A., Goncalves, L., Corvo, M. and Almeida, A. (2012) Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems. Vaccine 30: 6551-6558.
52. Garcon, N. and Van Mechelen, M. (2011) Recent clinical experience with vaccines using MPLand QS-21-containing adjuvant systems. Expert Rev Vaccines 10: 471-486.
53. Gluck, R. (1992) Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 10: 915-919.
54. Gluck, R., Burri, K. and Metcalfe, I. (2005) Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv 2: 395-400.
55. Gluck, R. and Walti, E. (2000) Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). Dev Biol (Basel) 103: 189-197.
56. Gowen, B., Fairman, J., Dow, S., Troyer, R., Wong, M., Jung, K. et al. (2009) Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res 81: 37-46.
57. Gregory, A., Titball, R. and Williamson, D. (2013) Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 3: 13.
58. Gupta, P. and Vyas, S. (2011) Investigation of lectinized liposomes as M-cell targeted carrieradjuvant for mucosal immunization. Colloids Surf B Biointerfaces 82: 118-125.
59. Hansen, J., Lindenstrom, T., Lindberg-Levin, J., Aagaard, C., Andersen, P. and Agger, E. (2012) CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice. Cancer Immunol Immunother 61: 893-903.
60. Hebishima, T., Yuba, E., Kono, K., Takeshima, S., Ito, Y. and Aida, Y. (2012) The pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly(glycidol)-conjugated liposome induces antigenspecific cellular and humoral immunity. Clin Vaccine Immunol 19: 1492-1498.
61. Heegaard, P., Dedieu, L., Johnson, N., Le Potier, M., Mockey, M., Mutinelli, F. et al. (2011) Adjuvants and delivery systems in veterinary vaccinology: current state and Future developments. Arch Virol 156: 183-202.
62. Helenius, A., Fries, E. and Kartenbeck, J. (1977) Reconstitution of Semliki Forest virus membrane. J Cell Biol 75: 866-880.
63. Henriksen-Lacey, M., Bramwell, V., Christensen, D., Agger, E., Andersen, P. and Perrie, Y. (2010) Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 142: 180-186.
64. Henriksen-Lacey, M., Christensen, D., Bramwell, V., Lindenstrom, T., Agger, E., Andersen, P. et al. (2011) Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N’,N’-dimethylaminoethane) carbomyl] cholesterol (DC-CHOL), and 1,2-dioleoyl3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol Pharm 8: 153-161.
65. Herzog, C., Hartmann, K., Kunzi, V., Kursteiner, O., Mischler, R., Lazar, H. et al. (2009) Eleven years of inflexal V-A virosomal adjuvanted influenza vaccine. Vaccine 27: 4381-4387.
66. Hiszczynska-Sawicka, E., Li, H., Boyu Xu, J., Akhtar, M., Holec-Gasior, L., Kur, J. et al. (2012) Induction of immune responses in sheep by vaccination with liposome-entrapped DNA complexes encoding Toxoplasma gondii MIC3 gene. Pol J Vet Sci 15: 3-9.
67. Hong, D., Chang, S., Botham, C., Giffon, T., Fairman, J. and Lewis, D. (2010) Cationic lipid/DNA complex-adjuvanted influenza a virus vaccination induces robust cross-protective immunity. J Virol 84: 12691-12702.
68. Ichihashi, T., Satoh, T., Sugimoto, C. and Kajino, K. (2013) Emulsified phosphatidylserine, simple and effective peptide carrier for induction of potent epitope-specific T cell responses. PLoS One 8: e60068
69. Ingvarsson, P., Schmidt, S., Christensen, D., Larsen, N., Hinrichs, W., Andersen, P. et al. (2013) Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01. J Control Release 167: 256-264.
70. Ingvarsson, P., Yang, M., Nielsen, H., Rantanen, J. and Foged, C. (2011) Stabilization of liposomes during drying. Expert Opin Drug Deliv 8: 375-388.
71. Irache, J., Salman, H., Gamazo, C. and Espuelas, S. (2008) Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 5: 703-724.
72. Jain, V., Vyas, S. and Kohli, D. (2009) Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives. Nanomedicine 5: 334-344.
73. Jamali, A., Holtrop, M., De Haan, A., Hashemi, H., Shenagari, M., Memarnejadian, A. et al. (2012) Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunol Lett 148: 77-82.
74. Jones, A., Bosio, C., Duffy, A., Goodyear, A., Schriefer, M. and Dow, S. (2010) Protection against pneumonic plague following oral immunization with a non-replicating vaccine. Vaccine 28: 5924-5929.
75. Joshi, M., Unger, W., Storm, G., Van Kooyk, Y. and Mastrobattista, E. (2012) Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release 161: 25-37.
76. Kamath, A., Mastelic, B., Christensen, D., Rochat, A., Agger, E., Pinschewer, D. et al. (2012) Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/ Th17 responses. J Immunol 188: 4828-4837.
77. Kamphuis, T., Shafique, M., Meijerhof, T., Stegmann, T., Wilschut, J. and De Haan, A. (2013) Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid a in mice and cotton rats. Vaccine 31: 2169-2176.
78. Kamphuis, T., Stegmann, T., Meijerhof, T., Wilschut, J. and De Haan, A. (2013) A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid a provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza Other Respir Viruses 7: 1227-1236.
79. Karlsson, I., Brandt, L., Vinner, L., Kromann, I., Andreasen, L., Andersen, P. et al. (2013) Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1Infection. Clin Immunol 146: 120-130.
80. Kaur, R., Bramwell, V., Kirby, D. and Perrie, Y. (2012) Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/ Th2 immune responses. J Control Release 158: 72-77.
81. Kawai, T. and Akira, S. (2010) The role of patternrecognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
82. Kheiri, M., Jamali, A., Shenagari, M., Hashemi, H., Sabahi, F., Atyabi, F. et al. (2012) Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge. Antiviral Res 95: 229-236.
83. Korsholm, K., Andersen, P. and Christensen, D. (2012) Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status. Expert Rev Vaccines 11: 561-577.
84. Kozako, T., Arima, N., Yoshimitsu, M., Honda, S. and Soeda, S. (2012) Liposomes and nanotechnology in drug development: focus on oncotargets. Int J Nanomedicine 7: 4943-4951.
85. Krishnamachari, Y. and Salem, A. (2009) Innovative strategies for co-delivering antigens and CPG oligonucleotides. Adv Drug Deliv Rev 61: 205-217.
86. Krishnan, L., Dicaire, C., Patel, G. and Sprott, G. (2000) Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect Immun 68: 54-63.
87. Krishnan, L. and Sprott, G. (2008) Archaeosome adjuvants: immunological capabilities and mechanism(s) of action. Vaccine 26: 2043-2055.
88. Lakshminarayanan, V., Thompson, P., Wolfert, M., Buskas, T., Bradley, J., Pathangey, L. et al. (2012) Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 109: 261-266.
89. Lay, M., Callejo, B., Chang, S., Hong, D., Lewis, D., Carroll, T. et al. (2009) Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 27: 3811-3820.
90. Leroux-Roels, G. (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28 Suppl. 3: C25-36.
91. Leroux-Roels, G., Maes, C., Clement, F., Van Engelenburg, F., Van Den Dobbelsteen, M., Adler, M. et al. (2013) Randomized phase I: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 GP41 P1 peptide on virosomes. PLoS One 8: e55438.
92. Li, P., Chen, S., Jiang, Y., Jiang, J., Zhang, Z. and Sun, X. (2013) Dendritic cell targeted liposomesprotamine-DNA complexes mediated by synthetic mannosylated cholesterol as a potential carrier for DNA vaccine. Nanotechnology 24: 295101.
93. Li, Y., Hu, Y., Jin, Y., Zhang, G., Wong, J., Sun, L. et al. (2011) Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated polcyclic on highly pathogenic H5N1 influenza infection. J Gene Med 13: 60-72.
94. Lin, Y., Deng, M., Tseng, L., Jiang, P., Jan, T., Hsieh, F. et al. (2011) Adjuvant effect of liposome in chicken result from induction of nitric oxide. Biomed Mater 6: 015011.
95. Lin, Y., Slight, S. and Khader, S. (2010) Th17 cytokines and vaccine-induced immunity. Semin Immunopathol 32: 79-90.
96. Lindenstrom, T., Woodworth, J., Dietrich, J., Aagaard, C., Andersen, P. and Agger, E. (2012) Vaccine-induced Th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect Immun 80: 3533-3544.
97. Liu, H., De Vries-Idema, J., Ter Veer, W., Wilschut, J. and Huckriede, A. (2013) Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen Dose sparing. Med Microbiol Immunol 203: 47-55.
98. Liu, J., Wu, J., Wang, B., Zeng, S., Qi, F., Lu, C. et al. (2014) Oral vaccination with a liposomeencapsulated influenza DNA vaccine protects mice against respiratory challenge infection. J Med Virol 86: 886-894.
99. Logue, C., Phillips, A., Mossel, E., Ledermann, J., Welte, T., Dow, S. et al. (2010) Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal western equine encephalitis virus (WEEV) challenge. Antiviral Res 87: 195-203.
100. Lonez, C., Vandenbranden, M. and Ruysschaert, J. (2012) Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev 64: 1749-1758.
101. Ludewig, B., Barchiesi, F., Pericin, M., Zinkernagel, R., Hengartner, H. and Schwendener, R. (2000) In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 19: 23-32.
102. Ma, Y., Zhuang, Y., Xie, X., Wang, C., Wang, F., Zhou, D. et al. (2011) The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 3: 2307-2314.
103. Mandal, M., Kawamura, K., Wherry, E., Ahmed, R. and Lee, K. (2004) Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm 1: 2-8.
104. Mandal, M. and Lee, K. (2002) Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta 1563: 7-17.
105. Martel, C., Agger, E., Poulsen, J., Hammer Jensen, T., Andresen, L., Christensen, D. et al. (2011) Caf01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. PLoS One 6: e22891
106. Masek, J., Bartheldyova, E., Turanek-Knotigova, P., Skrabalova, M., Korvasova, Z., Plockova, J. et al. (2011) Metallochelating liposomes with associated lipophilised norAbuMDP as biocompatible platform for construction of vaccines with recombinant histagged antigens: preparation, structural study and immune response towards rHsp90. J Control Release 151: 193-201.
107. McAleer, J. and Vella, A. (2010) Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. Trends Immunol 31: 429-435.
108. Milicic, A., Kaur, R., Reyes-Sandoval, A., Tang, C., Honeycutt, J., Perrie, Y. et al. (2012) Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses. PLoS One 7: e34255.
109. Miyazaki, J., Nishiyama, H., Yano, I., Nakaya, A., Kohama, H., Kawai, K. et al. (2011) The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res 31: 2065-2071.
110. Mizuuchi, M., Hirohashi, Y., Torigoe, T., Kuroda, T., Yasuda, K., Shimizu, Y. et al. (2012) Novel oligomannose liposome-DNA complex DNA vaccination efficiently Evokes anti-HPV E6 and E7 CTL responses. Exp Mol Pathol 92: 185-190.
111. Moon, J., Suh, H., Bershteyn, A., Stephan, M., Liu, H., Huang, B. et al. (2011) Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 10: 243-251.
112. Morrey, J., Motter, N., Chang, S. and Fairman, J. (2011) Breaking B and T cell tolerance using cationic lipid-DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antiviral Res 90: 227-230.
113. Moser, C., Muller, M., Kaeser, M., Weydemann, U. and Amacker, M. (2013) Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines 12: 779-791.
114. Moser, M. and Leo, O. (2010) Key concepts in immunology. Vaccine 28 Suppl. 3: C2-C13.
115. Nagill, R. and Kaur, S. (2010) Enhanced efficacy and immunogenicity of 78 kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine 28: 4002-4012.
116. Nakamura, T., Yamazaki, D., Yamauchi, J. and Harashima, H. (2013) The nanoparticulation by octaarginine-modified liposome improves alphagalactosylceramide-mediated antitumor therapy via systemic administration. J Control Release 171: 216-224.
117. Nishimura, M., Kohara, J., Kuroda, Y., Hiasa, J., Tanaka, S., Muroi, Y. et al. (2013) Oligomannosecoated liposome-entrapped dense granule protein 7 induces protective immune response to Neospora caninum in cattle. Vaccine 31: 3528-3535.
118. Nordly, P., Agger, E., Andersen, P., Nielsen, H. and Foged, C. (2011) Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDP liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. Pharm Res 28: 553-562.
119. Nordly, P., Madsen, H., Nielsen, H. and Foged, C. (2009) Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin Drug Deliv 6: 657-672.
120. North, S. and Butts, C. (2005) Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 4: 249-257.
121. North, S., Graham, K., Bodnar, D. and Venner, P. (2006) A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 176: 91-95.
122. Ogawa, C., Liu, Y. and Kobayashi, K. (2011) Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. Curr Bioact Compd 7: 180-197.
123. Ohyanagi, F., Horai, T., Sekine, I., Yamamoto, N., Nakagawa, K., Nishio, M. et al. (2011) Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a phase I/II study. Jpn J Clin Oncol 41: 718-722.
124. Onuigbo, E., Okore, V., Ofokansi, K., Okoye, J., Nworu, C., Esimone, C. et al. (2012) Preliminary evaluation of the immunoenhancement potential of Newcastle disease vaccine formulated as a cationic liposome. Avian Pathol 41: 355-360.
125. Oussoren, C., Zuidema, J., Crommelin, D. and Storm, G. (1997) Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1328: 261-272.
126. Pang, Y., Zhang, Y., Wang, H., Jin, J., Piao, J., Piao, J. et al. (2013) Reduction of Salmonella enteritidis number after infections by immunization of liposomeassociated recombinant SEFA. Avian Dis 57: 627-633.
127. Patel, G. and Chen, W. (2010) Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Rev Vaccines 9: 431-440.
128. Patel, G., Zhou, H., Kuolee, R. and Chen, W. (2004) Archaeosomes as adjuvants for combination vaccines. J Liposome Res 14: 191-202.
129. Peduzzi, E., Westerfeld, N., Zurbriggen, R., Pluschke, G. and Daubenberger, C. (2008) Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin Immunol 127: 188-197.
130. Perche, F., Benvegnu, T., Berchel, M., Lebegue, L., Pichon, C., Jaffres, P. et al. (2011) Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7: 445-453.
131. Perez, O., Romeu, B., Cabrera, O., Gonzalez, E., Batista-Duharte, A., Labrada, A. et al. (2013) Adjuvants are key factors for the development of future vaccines: lessons from the Finlay adjuvant platform. Front Immunol 4: 407.
132. Phillips, A., Schountz, T., Toth, A., Rico, A., Jarvis, D., Powers, A. et al. (2014) Liposome-antigennucleic acid Complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses. J Virol 88: 1771-1780.
133. Pichon, C. and Midoux, P. (2013) Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA. Methods Mol Biol 969: 247-274.
134. Puangpetch, A., Anderson, R., Huang, Y., Sermswan, R., Chaicumpa, W., Sirisinha, S. et al. (2012) Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/C mice. Clin Vaccine Immunol 19: 675-683.
135. Ravindran, R., Maji, M. and Ali, N. (2012) Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Mol Pharm 9: 59-70.
136. Reed, S., Orr, M. and Fox, C. (2013) Key roles of adjuvants in modern vaccines. Nat Med 19: 1597-1608.
137. Ribeiro, A., Souza, A., Amaral, A., Vasconcelos, N., Jeronimo, M., Carneiro, F. et al. (2013) Nanobiotechnological approaches to delivery of DNA vaccine against fungal infection. J Biomed Nanotechnol 9: 221-230.
138. Rizwan, S., McBurney, W., Young, K., Hanley, T., Boyd, B., Rades, T. et al. (2013) Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release 165: 16-21.
139. Rodriguez, A., Zamorano, P., Wilkowsky, S., Torra, F., Ferreri, L., Dominguez, M. et al. (2013) Delivery of recombinant vaccines against bovine herpesvirus type 1 gD and Babesia bovis MSA-2c to mice using liposomes derived from egg yolk lipids. Vet J 196: 550-551.
140. Roman, V., Jensen, K., Jensen, S., Leo-Hansen, C., Jespersen, S., Da Silva Te, D. et al. (2013) Therapeutic vaccination using cationic liposomeadjuvanted HIV type 1 peptides representing HLAsupertype-restricted subdominant T cell epitopes: safety, immunogenicity, and Feasibility in GuineaBissau. AIDS Res Hum Retroviruses 29: 1504-1512.
141. Rosenkrands, I., Vingsbo-Lundberg, C., Bundgaard, T., Lindenstrom, T., Enouf, V., Van Der Werf, S. et al. (2011) Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29: 6283-6291.
142. Roulois, D., Gregoire, M. and Fonteneau, J. (2013) MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. Biomed Res Int 2013: 871936.
143. Saksawad, R., Likitnukul, S., Warachit, B., Hanvivatvong, O., Poovorawan, Y. and Puripokai, P. (2011) Immunogenicity and safety of a pediatric dose virosomal hepatitis a vaccine in Thai HIV-infected children. Vaccine 29: 4735-4738.
144. Sarkar, S., Salyer, A., Wall, K. and Sucheck, S. (2013) Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes. Bioconjug Chem 24: 363-375.
145. Schwendener, R., Ludewig, B., Cerny, A. and Engler, O. (2010) Liposome-based vaccines. Methods Mol Biol 605: 163-175.
146. Schweneker, K., Gorka, O., Schweneker, M., Poeck, H., Tschopp, J., Peschel, C. et al. (2013) The mycobacterial cord factor adjuvant analogue trehalose-6,6’-dibehenate (TDB) activates the NLRP3 inflammasome. Immunobiology 218: 664-673.
147. Senchi, K., Matsunaga, S., Hasegawa, H., Kimura, H. and Ryo, A. (2013) Development of oligomannosecoated liposome-based nasal vaccine against human parainfluenza virus type 3. Front Microbiol 4: 346.
148. Shargh, V., Jaafari, M., Khamesipour, A., Jaafari, I., Jalali, S., Abbasi, A. et al. (2012) Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine 30: 3957-3964.
149. Shirota, H. and Klinman, D. (2014) Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines 13: 299-312.
150. Singha, H., Mallick, A., Jana, C., Fatima, N., Owais, M. and Chaudhuri, P. (2011) Co-immunization with interlukin-18 enhances the protective efficacy of liposomes encapsulated recombinant Cu-Zn superoxide dismutase protein against Brucella abortus. Vaccine 29: 4720-4727.
151. Smith, D., Simon, J. and Baker, J., Jr. (2013) Applications of nanotechnology for immunology. Nat Rev Immunol 13: 592-605.
152. Spang, A., Martijn, J., Saw, J., Lind, A., Guy, L. and Ettema, T. (2013) Close encounters of the third domain: the emerging genomic view of archaeal diversity and evolution. Archaea 2013: 202358.
153. Sprott, G., Yeung, A., Dicaire, C., Yu, S. and Whitfield, D. (2012) Synthetic archaeosome vaccines containing triglycosylarchaeols can provide additive and long-lasting immune responses that are enhanced by archaetidylserine. Archaea 2012: 513231.
154. Sun, X., Provoda, C. and Lee, K. (2010) Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: its utility in cytotoxic T lymphocyte-inducing DNA vaccine. J Control Release 148: 219-225.
155. Takagi, A., Kobayashi, N., Taneichi, M., Uchida, T. and Akatsuka, T. (2013) Coupling to the surface of liposomes alters the immunogenicity of hepatitis C virus-derived peptides and confers sterile immunity. Biochem Biophys Res Commun 430: 183-189.
156. Tamborrini, M., Stoffel, S., Westerfeld, N., Amacker, M., Theisen, M., Zurbriggen, R. et al. (2011) Immunogenicity of a virosomally-formulated plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J 10: 359.
157. Taneichi, M., Tanaka, Y., Kakiuchi, T. and Uchida, T. (2010) Liposome-coupled peptides induce longlived memory CD8 T cells without CD4 T cells. PLoS One 5: e15091.
158. Thakur, A., Aagaard, C., Stockmarr, A., Andersen, P. and Jungersen, G. (2013) Cell-mediated and humoral immune responses after immunization of calves with a recombinant multiantigenic Mycobacterium avium subsp. paratuberculosis subunit vaccine at different ages. Clin Vaccine Immunol 20: 551-558.
159. Thomann, J., Heurtault, B., Weidner, S., Braye, M., Beyrath, J., Fournel, S. et al. (2011) Antitumor activity of liposomal ERBB2/HER2 epitope peptidebased vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 32: 4574-4583.
160. Torchilin, V.P. (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160.
161. Traub, S., Von Aulock, S., Hartung, T. and Hermann, C. (2006) MDP and other muropeptides direct and synergistic effects on the immune system. J Endotoxin Res 12: 69-85.
162. Tseng, L., Liang, H., Deng, M., Lee, K., Pan, R., Yang, J. et al. (2010) The influence of liposomal adjuvant on intranasal vaccination of chickens against Newcastle disease. Vet J 185: 204-210.
163. Underwood, C. and Van Eps, A. (2012) Nanomedicine and veterinary science: the reality and the practicality. Vet J 193: 12-23.
164. Van Den Berg, J., Oosterhuis, K., Hennink, W., Storm, G., Van Der Aa, L., Engbersen, J. et al. (2010) Shielding the cationic charge of nanoparticleformulated dermal DNA vaccines is essential for antigen expression and immunogenicity. J Control Release 141: 234-240.
165. Walczak, M., De Mare, A., Riezebos-Brilman, A., Regts, J., Hoogeboom, B., Visser, J. et al. (2011) Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. Mol Pharm 8: 65-77.
166. Wang, C., Zhuang, Y., Zhang, Y., Luo, Z., Gao, N., Li, P. et al. (2012) Toll-like receptor 3 agonist complexed with cationic liposome augments vaccineelicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 30: 4790-4799.
167. Watson, D., Endsley, A. and Huang, L. (2012) Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 30: 2256-2272.
168. Watson, D., Platt, V., Cao, L., Venditto, V. and Szoka, F., Jr. (2011) Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice. Clin Vaccine Immunol 18: 289-297.
169. Werninghaus, K., Babiak, A., Gross, O., Holscher, C., Dietrich, H., Agger, E. et al. (2009) Adjuvanticity of a synthetic cord factor analogue for subunit mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 206: 89-97.
170. Woese, C. and Fox, G. (1977) Phylogenetic structure of the prokaryotic domain: the primary kingdoms. Proc Natl Acad Sci U S A 74: 5088-5090.
171. Wu, Y., Park, K., Soo, R., Sun, Y., Tyroller, K., Wages, D. et al. (2011) Inspire: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 11: 430.
172. Yaguchi, K., Ohgitani, T., Noro, T., Kaneshige, T. and Shimizu, Y. (2009) Vaccination of chickens with liposomal inactivated avian pathogenic Escherichia coli (APEC) vaccine by eye drop or coarse spray administration. Avian Dis 53: 245-249.
173. Yanasarn, N., Sloat, B. and Cui, Z. (2011) Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Mol Pharm 8: 1174-1185.
174. Yu, B., Mao, Y., Bai, L., Herman, S., Wang, X., Ramanunni, A. et al. (2013) Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 121: 136-147.
175. Yu, H., Karunakaran, K., Jiang, X., Shen, C., Andersen, P. and Brunham, R. (2012) Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun 80: 1510-1518.
176. Yu, Y., Wang, D., Abula, S., Hu, Y., Zhao, X., Huang, Y. et al. (2013) The immunological adjuvant activity of gypenosides liposome against Newcastle disease vaccine. Int J Biol Macromol 60: 116-121.
177. Zaman, M., Good, M. and Toth, I. (2013) Nanovaccines and their mode of action. Methods 60: 226-231.
178. Zepp, F. (2010) Principles of vaccine design lessons from nature. Vaccine 28 Suppl. 3: C14-C24.
179. Zhao, X., Fan, Y., Wang, D., Hu, Y., Guo, L., Ruan, S. et al. (2011) Immunological adjuvant efficacy of glycyrrhetinic acid liposome against Newcastle disease vaccine. Vaccine 29: 9611-9617.
180. Zhong, Z., Wei, X., Qi, B., Xiao, W., Yang, L., Wei, Y. et al. (2010) A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice. Int J Pharm 399: 156-162.
181. Zhuang, Y., Ma, Y., Wang, C., Hai, L., Yan, C., Zhang, Y. et al. (2012) Pegylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution. J Control Release 159: 135-142